On behalf of Mount Sinai, we would like to thank everyone for their participation and support for the COVID-19 hyperimmune globulin (HIG) program. Thanks to this community, we reached our goal for collection of high-quality convalescent plasma. Although the inpatient trials of receiving HIG have shown similar results to convalescent plasma trials, we are still assessing its use as a treatment in outpatient care as well as for prevention. We are very optimistic there will be important uses for COVID-19 HIG and hope the community will continue to support further trials.
Thank you for your continued support.
Copyright © 2021 Covidserum - All Rights Reserved.